Fortrea Holdings Inc. is a provider of clinical development and patient access solutions to the life sciences industry. It provides phase I-IV clinical trial management, clinical pharmacology, differentiated technology enabled trial solutions and post-approval services. Fortrea Holdings Inc. is based in DURHAM, N.C.
| Revenue (Most Recent Fiscal Year) | $2.70B |
| Net Income (Most Recent Fiscal Year) | $-328.50M |
| PE Ratio (Current Year Earnings Estimate) | 9.96 |
| PE Ratio (Trailing 12 Months) | 10.45 |
| PEG Ratio (Long Term Growth Estimate) | 0.28 |
| Price to Sales Ratio (Trailing 12 Months) | 0.14 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.44 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 2.66 |
| Pre-Tax Margin (Trailing 12 Months) | -27.83% |
| Net Margin (Trailing 12 Months) | -29.43% |
| Return on Equity (Trailing 12 Months) | 2.84% |
| Return on Assets (Trailing 12 Months) | 1.06% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.97 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.97 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 1.22 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $9.49 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.02 |
| Earnings per Share (Most Recent Fiscal Year) | $0.33 |
| Diluted Earnings per Share (Trailing 12 Months) | $-8.79 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 90.50M |
| Free Float | 90.39M |
| Market Capitalization | $378.29M |
| Average Volume (Last 20 Days) | 3.49M |
| Beta (Past 60 Months) | 2.15 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.12% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |